Αρχική World News FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection World News FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection Από Ogkologos - 7 Φεβρουαρίου, 2025 925 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-67T study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Can AI Help Predict Which Cancer Patients Should Be Treated with... 26 Φεβρουαρίου, 2025 EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment... 5 Οκτωβρίου, 2021 Cancer Research UK thanks Tania Bryer for a decade of fundraising... 19 Απριλίου, 2022 Mom Births Stillborn Baby But Never Anticipated Nurse’s Remark She Will... 15 Μαρτίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did... Deaf Football Team Makes History, Heads To School’s First Finals Game... Cancer “Liquid Biopsy” Blood Test Gets Expanded FDA Approval Darolutamide Delays the Spread of Some Prostate Cancers